State Secretariat for Education and Research SER
Federal Administration admin.ch
Federal Department of Home Affairs FDHA
State Secretariat for Education and Research SER

Questionnaire

Important information: Change of input strategy

The European Commission (EC) has informed that in connection with the Europe 2020 vision, there have been substantial changes of policies. Thus, the strategy for giving input to future Calls will not remain the same as in previous years. The EC emphasises that they are not looking for lists of topics and will not respond to any topic suggestions as under the new policy directives this would no longer be productive.

  • Below, you find the preliminary information of the upcoming FP7-Health Work Porgramme 2013.
  • Not all of the areas will be open (as indicated below).

  • Please indicate your comments and suggestions relating to the proposed foci of WP 2013 in the corresponding boxes!

  • You only need to fill in the boxes relating to your research field.
  • To make your arguments stronger: please indicate also partners from other countries which share your opinion (Name, Institution, Country)!
  • Your input is directly transmitted to the Swiss delegate for the FP7-Health Programme and will then be sent in a consolidated form to the European Commission (will be treated confidentially!).
  • All the best for your research and good luck!

1. Biotechnology, generic tools and technologies

 
1.1 High Throughput Research Closed (area substantially supported in calls 1-5).
  Focus on:
  • Imaging technologies for personalised & individualised medicine applications (“imaging biomarkers” for guiding medical interventions; involvement of end users is encouraged; applications on neurosciences/brain excluded as a dedicated action foreseen under 2.2.1) [SME target 15%].
1.2 Detection, diagnosis and monitoring
  Predictive human safety assessment:
  • Identification of key pathways of chronic toxic actions; identification of novel markers of toxicity at molecular,cellular and physiological level (SME target 15%).
  • Development of experimental and computational models for quantitative prediction of toxicity (SME target 50%).
  • New approaches for safety testing for vaccine development(SME target 30%).
  • Systems approaches to characterize adverse immune responses: autoimmune diseases, chronic inflammations, allergies; cancer excluded as a dedicated action is foreseen under 2.4.1. (SME target 30%).
1.3 Suitability, safety and efficacy of medicines
 
1.4 Innovative therapeutic approaches and interventions Closed (in Work Programme 2013).
 

2. Translating research for human health

 
  Focus on:
  • Functional validation in cellular and/or animal models of genetic determinants of diseases and ageing processes(large scale phenotyping into model systems/organisms, generation of humanised models, new phenotyping technologies, common ontology, transfer of knowledge)[SME target 15%].
  • Metagenomics for Personalised Medicine approaches(exploring and exploiting links between microbiome and chronic diseases by metagenome profiling studies in large cohorts) [SME target 15%].
2.1.1 Large scale data gathering
 
2.1.2 Systems biology Closed (in Work Programme 2013).
 
  Focus on SMEs involvement and clinical research:
  • Prospective data collection and comparative effectiveness research for traumatic brain injury (TBI) – programme level cooperation with US, CAN - towards an International Initiative for TBI Research (InTBIR).
  • Imaging tools for diagnosis and monitoring of psychiatric disorders (SME target, 30%).
  • Paediatric behavioural disorders characterised by aggressive and/or anti-social traits: from preclinical research to treatment (SME target, 15%).
  • Patho-physiology and therapy of epilepsy.
2.2.1 Brain
 
2.2.2 Human development and ageing Closed (in Work Programme 2013, actions related to aging are included under other areas).
 
  Focus on:
  • Innovative vaccines and tools for rapid vaccine production: a.) against pathogens potentially causing drug resistance, and b.) in response to pandemics SBIR-like scheme, SME target, 50%).
  • Mapping of drug resistance in developing countries.
2.3.0 Infectious diseases: cross-cutting issues
  Focus on:
  • Novel antimicrobials (SME target, 50 %).
  • Stratified approaches for pathogen host interactions.
  • Support for the JPI AMR (CSA) (possibly included in WP2012 update).
2.3.1 Anti-microbial drug resistance
 
2.3.2 HIV/AIDS, TB, Malaria Closed (in Work Programme 2013).
 
  Focus on:
  • Clinical network for the management of new and emerging epidemics.
2.3.3 New and re-emerging epidemics
  Focus on:
  • Clinical development of vaccines for NID of European importance (SME target, 15%).
  • Drug development for parasitic diseases (SME target, 15%).
  • Novel approaches for the prevention and treatment of respiratory diseases in neonates in low resource setting in developing countries.
2.3.4 Neglected infectious diseases
  Focus on:
  • Enhancing patient-centred cancer immunotherapy: tumour-microenvironment, immune evasion, localised versus systemic disease (SME target, 50%)
  • Investigator-driven treatment trials for metastatic cancers SME target 15%)
  • Clinical trials for supportive and palliative care (SME target 15%)
2.4.1 Cancer
  Focus on:
  • Discovery research to reveal novel targets for CVD treatment using available “-omics” knowledge (SME target 30%).
  • Comparative effectiveness research of existing imaging detection tools and technologies used for prediction, diagnosis, monitoring and prognosis of CVD.
2.4.2 Cardiovascular diseases
 
2.4.3 Diabetes and obesity Closed (in Work Programme 2013)
 
 
2.4.4 Rare diseases Closed (in Work Programme 2013)
 
 
2.4.5 Other chronic diseases Closed (in Work Programme 2013)
 
 
3. Optimising the delivery of healthcare
 
  Focus on:
  • Comparative effectiveness research
  • Health technology assessments for chronic diseases in the context of the aging population
3.1. Translating clinical research into clinical practice
 
3.2. Health care systems Closed (in Work Programme 2013)
 
  Focus on:
  • Social innovation for health promotion with special attention to physical activity.
3.3. Enhanced health promotion and disease prevention
 
3.4. International public health research Closed (in Work Programme 2013)
 
 
4. Actions across the theme
 
  Priorities:
  • SA: Support network for high-technology research performing SMEs (Similar to “fit-for-health” project ending in 2013)
  • SA: Impact of legislation on research (Similar to earlier topic)
  • SA: Support for presidency events (e.g., events formally linked to EU presidencies in 2013-2014)
  • CSA: in support of “Year of Mind and Brain” content to be developed)
4.1 Coordination and support actions across the theme
  Focus on:
  • Clinical trials using innovative age-appropriate delivery systems or formulations addressing one of the options below: a.)off-patent medicines for children addressing areas set out in Paediatric Medicines Priority List by EMA [15 % Industry targeted including SMEs], and b.) off patent medicines for the elderly [15 % Industry targeted including SMEs]
  • Adverse drug and vaccine reaction research [15 % SME targeted]
  • New methodologies for clinical trials in small populations(international cooperation for regulatory science)
4.2. Responding to EU policy needs
  Please, indicate general strategic comments or suggestions concerning the future Health Work Programmes:

General strategic comments

Please indicate your contact detail:

Title Forename Name
University / Company
Address 1
Address 2
ZIP / Postal Code      Town   
Country
E-Mail
Phone